New Experimental Drug Offers Hope for Rare, Deadly Autoimmune Lung Disease

Spread the Message

Read Time:4 Minute, 39 Second

March 12, 2026

NEW DELHI — Researchers have announced a potential breakthrough in the treatment of Idiopathic Inflammatory Myopathy–Associated Interstitial Lung Disease (IIM-ILD), a rare and often fatal autoimmune condition. A preclinical study published this week in Frontiers in Immunology reveals that an experimental drug, Nerandomilast, significantly reduced lung inflammation, prevented permanent scarring (fibrosis), and improved muscle function in animal models. By specifically targeting overactive B cells—the “command centers” of the immune system’s attack—the drug offers a precision-medicine approach to a disease that currently leaves doctors with few effective tools.

A High-Stakes Battle for Breath

Idiopathic Inflammatory Myopathies (IIM) are a group of rare autoimmune disorders characterized by chronic muscle inflammation and weakness. However, for many patients, the most dangerous complication occurs when the immune system turns its sights on the lungs. Up to 80% of IIM patients develop Interstitial Lung Disease (ILD), where the delicate air sacs become inflamed and eventually replaced by thick, stiff scar tissue.

In severe subtypes, such as anti-MDA5 dermatomyositis, the progression can be terrifyingly swift. Without aggressive intervention, patients can succumb to respiratory failure within months.

“The burden of IIM-ILD is immense,” says Dr. Songtao Gu, a pulmonologist at Tianjin Chest Hospital and a co-author of the study. “Current treatments like high-dose steroids and broad immunosuppressants often come with grueling side effects and simply don’t work fast enough for the most progressive cases.”

How Nerandomilast “Calms the Riot”

The new study, led by researchers at Nankai University, focused on Nerandomilast, a selective inhibitor of phosphodiesterase 4B (PDE4B).

To understand how it works, imagine the immune system as a crowd of people. In IIM-ILD, a specific group called B cells becomes agitated, shouting orders (autoantibodies) that cause the rest of the immune system to attack the body’s own muscle and lung tissue. Nerandomilast works by increasing levels of a molecule called cyclic adenosine monophosphate (cAMP) inside these cells.

In the world of cellular biology, cAMP acts like a “brake.” By boosting this brake, Nerandomilast suppresses the overactive signaling pathways (specifically PI3K/AKT and NF-κB) that drive B cells to multiply and cause damage.

“Unlike broad-spectrum drugs that might evict every immune cell from the building, Nerandomilast is more like a specialized team that goes in to turn off the amplifiers,” explains the research team. “It reprograms the B-cell network rather than just destroying it.”

Evidence from the Lab

In the study, researchers used mouse models that mimic the human version of myositis and lung disease. The mice were treated with varying doses of Nerandomilast and compared against those receiving nintedanib, a currently approved antifibrotic medication.

The results were striking:

Improved Lung Function: Micro-CT scans showed clearer lungs and significantly better ventilation. Tests for forced vital capacity (the amount of air a person can exhale after a deep breath) showed marked improvement.
Reduced Scarring: Histopathology confirmed lower collagen deposition—the “glue” that creates scars—in the lung tissue.
Muscle Recovery: Mice treated with the drug showed better grip strength and lower levels of muscle enzymes (CK and LDH), which typically spike when muscle tissue is being destroyed.
Autoantibody Reduction: Levels of anti-Jo-1, a key marker of the disease, were significantly reduced in the blood.

Expert Perspectives: Moving Toward Human Trials

While the preclinical results are promising, medical experts caution that the transition from mice to men is the ultimate test.

“The role of B cells in driving IIM-ILD is undeniable,” says Dr. Chester Oddis, a rheumatologist at the University of Pittsburgh, who was not involved in the study. “Targeting their activation without completely depleting them—as we do with current treatments like rituximab—could potentially reduce the risk of secondary infections and relapses.”

Dr. V. Sotiropoulou, an independent expert at Pneumon.org, adds: “PDE4 inhibitors are an exciting new frontier that could expand our options beyond steroids. However, we urgently need the data from ongoing human clinical trials to see if these survival benefits translate to our patients.”

Public Health and the Future of Care

For the approximately 1 in 100,000 people living with IIM-ILD, the development of a targeted therapy could represent a paradigm shift. If human trials (such as the ongoing FIBRONEER program) continue to show success, Nerandomilast could potentially be used in combination with existing therapies to stabilize lung function and preserve mobility.

In regions like India, where the prevalence of rheumatic diseases is significant and access to specialized intensive care can be limited, the availability of an oral, targeted medication could reduce the long-term burden on public health systems by preventing hospitalizations and the need for lung transplants.

Limitations and Next Steps

Despite the enthusiasm, researchers acknowledge several hurdles:

Animal Models: Mice do not perfectly replicate the complexity of human autoimmune diseases, particularly the “rapidly progressive” forms seen in some patients.
Safety: Long-term safety data in humans for this specific condition is still being gathered.
Heterogeneity: IIM-ILD presents differently in every patient; what works for one subtype may not work for another.

Clinical trials (NCT06806592) are currently underway to test the efficacy of Nerandomilast in patients with various types of progressive fibrosing interstitial lung diseases.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.